-
By Joseph E. Scherger, MD, MPH
Clinical Professor, University of California, San Diego
Disclosure; Dr. Scherger reports no financial conflicts to this field of study.
-
By Ralph R. Hall, MD, FACP
Emeritus Professor of Medicine, University of Missouri, Kansas City School of Medicine
Disclosure; Dr. Hall is a consultant for Sanofi-Aventis.
Synopsis: Exercise and stress management improved markers of cardiovascular disease more than usual care alone.
-
-
White-Coat HTN
Make Diabetics Walk
Treatment of Complicated Grief
-
By Norman R. Relkin, MD, PhD
Associate Professor of Clinical Neurology and Neuroscience at New York Presbyterian Hospital-Cornell Campus.
Dr. Relkin is on the speaker's bureau of Pfizer, Eisai, and Athena Diagnostics and does research for Pfizer and Merck.
-
Rifamixin, a nonabsorbed oral antibiotic, is effective for preventing traveler's diarrhea, according to new research.
-
-
By William T. Elliott, MD, FACP, and James Chan, PharmD, PhD
Dr. Elliott is Chair, Formulary Committee, Northern California Kaiser Permanente; Associate Clinical Professor of Medicine, University of California, San Francisco; Dr. Chan is Pharmacy Quality and Outcomes Manager, Kaiser Permanente, Oakland, CA. Drs. Chan and Elliott report no financial relationships to this field of study.
A synthetic analog of human amylin has been approved for the treatment of type 1 and type 2 diabetics.
Pramlintide is a 37-amino acid peptide which differs from human amylin with substitution of three amino acids at positions 25, 28, and 29. It represents the first of a new class of amylinomimetic antidiabetic compounds. It is marketed by Amylin Pharmaceuticals, Inc as Symlin.
-
Rewind to November 2004: the Food and Drug Administration (FDA) announces the addition of a black box warning to the labeling for the injectable contraceptive depot medroxyprogesterone acetate (DMPA, Depo-Provera, Pfizer, New York City and MedroxyPROGESTERone Injection, Teva Pharmaceuticals USA, North Wales, PA).
-
More women are choosing long-term birth control through use of intrauterine contraception, say participants in the 2005 Contraceptive Technology Update Contraception Survey.